A phase 3 trial found that tarlatamab plus durvalumab helped people with advanced small cell lung cancer live longer. The study compared the treatment with durvalumab alone.
← News
Medicine Breakthroughs Medicine Breakthroughs Health
Immunotherapy combo extends survival for patients with aggressive small cell lung cancer, based on trial results
Phase 3 Trial phase
First-Line Maintenance Treatment setting
Durvalumab Alone Comparison treatment
58% death risk reduction
More Than 8 Months median survival gain
More Than 3 Times progression-free survival